Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Cash from Financing Activities: 2012-2024

Historic Cash from Financing Activities for Rocket Pharmaceuticals (RCKT) over the last 13 years, with Dec 2024 value amounting to $185.7 million.

  • Rocket Pharmaceuticals' Cash from Financing Activities fell 138.07% to -$67,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $183.2 million, marking a year-over-year increase of 5482.84%. This contributed to the annual value of $185.7 million for FY2024, which is 10.87% down from last year.
  • According to the latest figures from FY2024, Rocket Pharmaceuticals' Cash from Financing Activities is $185.7 million, which was down 10.87% from $208.4 million recorded in FY2023.
  • In the past 5 years, Rocket Pharmaceuticals' Cash from Financing Activities registered a high of $283.0 million during FY2020, and its lowest value of $37.7 million during FY2021.
  • For the 3-year period, Rocket Pharmaceuticals' Cash from Financing Activities averaged around $183.1 million, with its median value being $185.7 million (2024).
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Cash from Financing Activities slumped by 86.68% in 2021, and later spiked by 312.11% in 2022.
  • Yearly analysis of 5 years shows Rocket Pharmaceuticals' Cash from Financing Activities stood at $283.0 million in 2020, then tumbled by 86.68% to $37.7 million in 2021, then soared by 312.11% to $155.3 million in 2022, then soared by 34.20% to $208.4 million in 2023, then dropped by 10.87% to $185.7 million in 2024.